JAC Advance Access originally published online on February 11, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 497-511
© 2003 The British Society for Antimicrobial Chemotherapy
Review Article |
Drugs of the 21st century: telithromycin (HMR 3647)—the first ketolide
Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Liebigstrasse 24, 04103 Leipzig, Germany
Telithromycin (HMR 3647) is the first ketolide introduced into clinical practice. Ketolides are semisynthetic derivates of erythromycin A that carry novel biological properties on the erythronolide A ring. This new class of antimicrobials was designed to overcome current resistance mechanisms against erythromycin A within Gram-positive cocci. Ketolides do not induce macrolide–lincosamide–streptogramin B (MLSB) resistance and are active against erythromycin resistance methylase gene (erm)-carrying Gram-positive cocci. This review summarizes published data on telithromycin and intends to define the challenge that a new antimicrobial brings to medical practice.
Keywords: new antimicrobials, telithromycin, resistance
* Corresponding author. Tel: +49-341-971-5200; Fax: +49-341-971-5209; E-mail: ackermg{at}medizin.uni-leipzig.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. C. Kouvela, D. L. Kalpaxis, D. N. Wilson, and G. P. Dinos Distinct Mode of Interaction of a Novel Ketolide Antibiotic That Displays Enhanced Antimicrobial Activity Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1411 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, H. Ouellet, D. H. Sherman, and L. M. Podust Analysis of Transient and Catalytic Desosamine-binding Pockets in Cytochrome P-450 PikC from Streptomyces venezuelae J. Biol. Chem., February 27, 2009; 284(9): 5723 - 5730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|
|
|
|
|
A. Al-Lahham, P. C. Appelbaum, M. van der Linden, and R. R. Reinert Telithromycin-Nonsusceptible Clinical Isolates of Streptococcus pneumoniae from Europe Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3897 - 3900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Karahalios, D. L. Kalpaxis, H. Fu, L. Katz, D. N. Wilson, and G. P. Dinos On the Mechanism of Action of 9-O-Arylalkyloxime Derivatives of 6-O-Mycaminosyltylonolide, a New Class of 16-Membered Macrolide Antibiotics Mol. Pharmacol., October 1, 2006; 70(4): 1271 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Sherman, S. Li, L. V. Yermalitskaya, Y. Kim, J. A. Smith, M. R. Waterman, and L. M. Podust The Structural Basis for Substrate Anchoring, Active Site Selectivity, and Product Formation by P450 PikC from Streptomyces venezuelae J. Biol. Chem., September 8, 2006; 281(36): 26289 - 26297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gibreel and D. E. Taylor Macrolide resistance in Campylobacter jejuni and Campylobacter coli J. Antimicrob. Chemother., August 1, 2006; 58(2): 243 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rantala, M. Haanpera-Heikkinen, M. Lindgren, H. Seppala, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistan Streptococcus pneumoniae Isolates Resistant to Telithromycin. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1855 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Johnston, F. Blasi, P. N. Black, R. J. Martin, D. J. Farrell, R. B. Nieman, and the TELICAST Investigators The Effect of Telithromycin in Acute Exacerbations of Asthma N. Engl. J. Med., April 13, 2006; 354(15): 1589 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rantala, S. Huikko, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistan Prevalence and Molecular Genetics of Macrolide Resistance among Streptococcus pneumoniae Isolates Collected in Finland in 2002 Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4180 - 4184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lippert, S. Gbenado, C. Qiu, B. Lavin, and S. J. Kovacs The Bioequivalence of Telithromycin Administered Orally as Crushed Tablets Versus Tablets Swallowed Whole J. Clin. Pharmacol., September 1, 2005; 45(9): 1025 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reed, G. C Wall, N. P Shah, J. M Heun, and G. A Hicklin Verapamil Toxicity Resulting from a Probable Interaction with Telithromycin Ann. Pharmacother., February 1, 2005; 39(2): 357 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Telithromycin Journal Watch Infectious Diseases, August 9, 2004; 2004(809): 9 - 9. [Full Text]
|
|
|
|
|
|
L. Drago, E. De Vecchi, L. Nicola, A. Colombo, and M. R. Gismondo Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides J. Antimicrob. Chemother., August 1, 2004; 54(2): 542 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert Clinical efficacy of ketolides in the treatment of respiratory tract infections J. Antimicrob. Chemother., June 1, 2004; 53(6): 918 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Low, M. E. Pichichero, and U. B. Schaad Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Jacobs, S. Bajaksouzian, and P. C. Appelbaum Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci J. Antimicrob. Chemother., November 1, 2003; 52(5): 809 - 812. [Abstract] [Full Text] [PDF]
|
|